Menu
Recruiting NCT03023202

UWCCC Molecular Tumor Board Registry

— Observational Hematologic Neoplasms Solid Neoplasm

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: PMMTB (Precision Medicine Molecular Tumor Board).
Who it may be relevant to
Registry conditions: Hematologic Neoplasms, Solid Neoplasm. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

UWCCC Precision Medicine Molecular Tumor Board Registry

Overview

This study seeks to evaluate the clinical utility of the Precision Medicine Molecular Tumor Board, and to track patient outcomes.

Interventions

  • Other PMMTB (Precision Medicine Molecular Tumor Board)
    PMMTB is a clinical intervention, NOT a research intervention. The research component of this study is to observe the outcomes of the PMMTB.

Primary outcome measures

  • Frequency of acceptance of molecular tumor board recommendations [Time frame: Up to 5 years]
  • Benefit from PMMTB recommended treatment [Time frame: Up to 5 years]
Secondary outcome measures (3)
  • Correlation of mutations with protein overexpression [Time frame: Up to 5 years]
  • Correlations of mutations with circulating tumor DNA [Time frame: Up to 5 years]
  • Correlations of mutations with spheroid culture investigations [Time frame: Up to 5 years]

Eligibility criteria

Inclusion criteria

  • Clinically suspected or histologically confirmed solid or hematological malignancy
  • Undergoing genetic testing of tumor
  • Ability to understand written informed consent document
  • Willingness to sign written informed consent document

Exclusion criteria

  • Pediatric patients (age<18 years) will be excluded due to a lack of expertise on the molecular tumor committee

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Case-only

Study locations

United States · 1 center
  • University of Wisconsin Carbone Cancer Center — Madison

Identifiers

NCT: NCT03023202 · 2015-1370 · P30CA014520 · 1R37CA226526-01A1 · NCI-2019-06343 · A533400 · SMPH\UWCCC\GENERAL · Protocol Version 3/24/24 · UW15068

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗